We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Overview of patent-statutory subject matter in biotechnology

  • CCPIT Patent & Trademark Law Office
  • -
  • China, European Union, Japan, USA
  • -
  • April 8 2013

With the advent of biotechnology, the human community stands on the threshold of an extraordinary revolution having profound

Protection for medical-related inventions in Japan

  • Shiga International Patent Office
  • -
  • Japan
  • -
  • April 8 2013

Japan has the second largest medical market in the world. For instance, there has been active development in recent years concerning regenerative

“Fat-blocking” soda launches in Japan

  • Shook Hardy & Bacon LLP
  • -
  • Japan
  • -
  • November 16 2012

PepsiCo, Inc

Japan - pharmaceutical law: advertising, gifts and hospitality - a shrinking territory

  • Clifford Chance LLP
  • -
  • Japan
  • -
  • September 7 2012

Advertising and promotion, gifts and hospitality: in Japan, companies are facing a thicket of rules designed to ensure the ethical promotion of medicinal products and medical devices and equipment

Patent term extensions and regulatory exclusivities for pharmaceuticals in Asia and South America

  • Morrison & Foerster LLP
  • -
  • Argentina, Brazil, Chile, China, Hong Kong, Japan, Malaysia, Mexico, Philippines, South Korea, Thailand, USA, Vietnam
  • -
  • June 27 2012

Patent protection for pharmaceutical products has an impact on the pharmaceutical market and innovation

Four rules for interacting with healthcare professionals in the Asia Pacific

  • Baker & McKenzie
  • -
  • Australia, China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
  • -
  • May 17 2012

Facing legal sanctions and cultural gaffes is a reality when dealing with healthcare professionals in the Asia Pacific

Japanese research institute claims BPA poses “very small” risk to human health

  • Shook Hardy & Bacon LLP
  • -
  • Japan
  • -
  • September 2 2011

A Japanese research institute recently issued an updated hazard assessment of bisphenol A (BPA) suggesting that the chemical poses minimal or no risk to human health

Japan raises nuclear alert level not seen since Chernobyl

  • Edwards Wildman Palmer LLP
  • -
  • Japan
  • -
  • April 12 2011

Japan is planning to raise the nuclear alert level at the Fukushima Daiichi power plant to a maximum seven ("Major Event") on the International Nuclear and Radiological Event Scale (INES), putting this emergency on a par with the 1986 Chernobyl disaster

Pharmaceutical Trademarks 20102011 - A Global Guide: Japan

  • Nishimura & Asahi
  • -
  • Japan
  • -
  • September 22 2010

Under the Pharmaceutical Affairs Law, sellers must obtain approval from either the Ministry of Health, Labour and Welfare (MHLW) or the prefecture in order to market pharmaceutical products, including drugs (defined in Article 2(1) of the law

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy